Clinical Importance of Body Composition in Improving Bone Mineral Density of Femoral Neck After Denosumab Therapy in Patients With Rheumatoid Arthritis or Collagen Diseases

In Vivo. 2022 May-Jun;36(3):1468-1476. doi: 10.21873/invivo.12853.

Abstract

Background/aim: To investigate factors associated with increased bone mineral density (BMD) of the neck of femur in rheumatoid arthritis or collagen diseases receiving denosumab, focusing on body composition calculated by bioelectrical impedance analysis (n=90, 78 females).

Patients and methods: We defined Δfemur as BMD (12 months minus baseline), using dual-energy X-ray absorptiometry after denosumab therapy. Factors associated with Δfemur were retrospectively investigated.

Results: Low skeletal muscle index (SMI) was observed in 6 males and 32 females. There was a significant difference in phase angle (PhA) of the left leg (LL) between the Δfemur ≥0 (n=70) and Δfemur <0 (n=20) groups (p=0.040) but not in SMI (p=0.310). Multiple regression analysis indicated that PhA of LL was significantly related to Δfemur (p=0.0398).

Conclusion: PhA appears to be a clinically significant indicator of improvement of Δfemur in patients receiving denosumab.

Keywords: Denosumab; body composition; bone mineral density; neck of femur; phase angle.

MeSH terms

  • Arthritis, Rheumatoid* / drug therapy
  • Body Composition / physiology
  • Bone Density
  • Collagen Diseases* / complications
  • Collagen Diseases* / drug therapy
  • Denosumab / adverse effects
  • Female
  • Femur Neck / diagnostic imaging
  • Humans
  • Male
  • Retrospective Studies

Substances

  • Denosumab